NCI-FDA Joint Training in Cancer Prevention

A group of CPFP fellows discussing additional research opportunities.

Cancer Prevention Fellows are eligible to participate in Track 4 of the Interagency Oncology Task Force Fellowship program—offered as a partnership of the National Cancer Institute and the Food and Drug Administration. Fellows learn to build awareness of regulatory requirements into the early stages of the medical product development and develop strategies to improve planning throughout research and regulatory review.

Track 4 of the fellowship provides training in cancer prevention and in the development of and approval processes for drugs, biologic agents, devices, or nutritional products.

Background and Rationale
In 2003, the NCI Director and the FDA Commissioner joined forces to more rapidly identify effective cancer preventive agents and cancer treatments, and accelerate their availability in the market. This joint commitment led to an initiative to train postdoctoral scientists and clinicians in research in cancer prevention, drug development, and regulatory review. Research training opportunities exist in several centers at the FDA.

The NCI-FDA joint training in cancer prevention will provide the opportunity for fellows to participate in all the activities of the CPFP at NCI, and in research and product development and regulatory review at the FDA. Combining training in public health, cancer prevention, product development, and regulatory research will allow individuals to develop expertise across these disciplines. This presents an opportunity to develop novel agents and products, design and implement clinical trials in chemoprevention and early detection, and advance nutritional sciences and other prevention-related activities.

Research Opportunities

Research topics may include, but are not limited to:

  • Cancer risk of drug, device, or gene therapy products
  • Cellular substrates in vaccine development
  • Clinical trial design and analytic methodology
  • Development and selection of biomarkers and clinical endpoints in clinical trials
  • Development of chemopreventive agents
  • Genetic toxicology and cancer prevention
  • Genomic and proteomic approaches to early detection of cancer
  • Molecular and genetic approaches in product development
  • Nutrition science and policy
  • Screening and early detection
  • Vaccination and cancer prevention

Learn more at https://www.cancer.gov/grants-training/training/at-nci/iotf.